After eight weeks, 52 per cent of those given JCM-16021 with Holopon reported reduced IBS symptoms, compared with 32 per cent of those given Holopon alone.
In 2007, Bian gave 80 people with IBS either JCM-16021 with Holopon - a drug that interrupts nerve impulses in the parasympathetic nervous system responsible for digestion - or Holopon alone.